Scilight Press

Author Information

Received: 06 Sep 2024 | Revised: 29 Sep 2024 | Accepted: 30 Sep 2024 | Published: 26 Nov 2024

Abstract

Keywords

immune checkpoints (ICPs) | CD4Foxp3 regulatory T cells (Tregs) | T cells | innate immune cells | cardiovascular diseases | cerebrovascular diseases

References 

• 1.
  Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12, 252–264. https://doi.org/10.1038/nrc3239.
• 2.
  Yang, X.F.; Mirkovic, D.; Zhang, S.; et al. Processing sites are different in the generation of HLA-A2.1-restricted, T cell reactive tumor antigen epitopes and viral epitopes. Int. J. Immunopathol. Pharmacol. 2006, 19, 853–870. https://doi.org/10.1177/039463200601900415.
• 3.
  Yan, Y.; Phan, L.; Yang, F.; et al. A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L. J. Immunol. 2004, 172, 651–660.
• 4.
  Yan, Y.; Chen, Y.; Yang, F.; et al. LA-A2.1-restricted T cells react to SEREX-defined tumor antigen CML66L and are suppressed by CD4+CD25+ regulatory T cells. Int. J. Immunopathol. Pharmacol. 2007, 20, 75–89. https://doi.org/10.1177/039463200702000109.
• 5.
  Yang, X.F.; Wu, C.J.; Chen, L.; et al. CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res. 2002, 62, 5517–5522.
• 6.
  Yang, X.F.; Wu, C.J.; McLaughlin, S.; et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc. Natl. Acad. Sci. USA. 2001, 98, 7492–7497. https://doi.org/10.1073/pnas.131590998.
• 7.
  Xiong, Z.; Liu, E.; Yan, Y.; et al. An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions. J. Immunol. 2006, 177, 4907–4916. https://doi.org/10.4049/jimmunol.177.7.4907.
• 8.
  Xiong, Z.; Liu, E.; Yan, Y.; et al. A novel unconventional antigen MPD5 elicits anti-tumor humoral immune responses in a subset of patients with polycythemia vera. Int. J. Immunopathol. Pharmacol. 2007, 20, 373–380. https://doi.org/10.1177/039463200702000218.
• 9.
  Xiong, Z.; Song, J.; Yan, Y.; et al. Higher expression of Bax in regulatory T cells increases vascular inflammation. Front. Biosci. 2008, 13, 7143–7155. https://doi.org/10.2741/3217.
• 10.
  Xiong, Z.; Yan, Y.; Liu, E.; et al. Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera. Clin. Immunol. 2007, 122, 279–287. https://doi.org/10.1016/j.clim.2006.10.006.
• 11.
  Yang, F.; Chen, I.H.; Xiong, Z.; et al. Model of stimulation-responsive splicing and strategies in identification of immunogenic isoforms of tumor antigens and autoantigens. Clin. Immunol. 2006, 121, 121–133. https://doi.org/10.1016/j.clim.2006.06.007.
• 12.
  Yang, F.; Yang X.F.New concepts in tumor antigens: Their significance in future immunotherapies for tumors. Cell Mol. Immunol.2005, 2, 331–341.
• 13.
  Yin, Y.; Li, X.; Sha, X.; et al. Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 804–816. https://doi.org/10.1161/ATVBAHA.115.305282.
• 14.
  Yin, Y.; Pastrana, J.L.; Li, X.; et al. Inflammasomes: Sensors of metabolic stresses for vascular inflammation. Front. Biosci. 2013, 18, 638–649.
• 15.
  Yin, Y.; Yan, Y.; Jiang, X.; et al. Inflammasomes are differentially expressed in cardiovascular and other tissues. Int. J. Immunopathol. Pharmacol. 2009, 22, 311–322. https://doi.org/10.1177/039463200902200208.
• 16.
  Paavonen, K.; Puolakkainen, P.; Jussila, L.; et al. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am. J. Pathol. 2000, 156, 1499–1504. https://doi.org/10.1016/S0002-9440(10)65021-3.
• 17.
  Reno, F.; Sabbatini, M. Breaking a Vicious Circle: Lymphangiogenesis as a New Therapeutic Target in Wound Healing. Biomedicines 2023, 11, 656. https://doi.org/10.3390/biomedicines11030656.
• 18.
  Xu, K.; Saaoud, F.; Shao, Y.; et al. Early hyperlipidemia triggers metabolomic reprogramming with increased SAH, increased acetyl-CoA-cholesterol synthesis, and decreased glycolysis. Redox Biol. 2023, 64, 102771. https://doi.org/10.1016/j.redox.2023.102771.
• 19.
  Drummer, C.I.V.; Saaoud, F.; Sun, Y.; et al. Hyperlipidemia May Synergize with Hypomethylation in Establishing Trained Immunity and Promoting Inflammation in NASH and NAFLD. J. Immunol. Res. 2021, 2021, 3928323. https://doi.org/10.1155/2021/3928323.
• 20.
  Wang, H.; Yoshizumi, M.; Lai, K.; et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J. Biol. Chem. 1997, 272, 25380–25385. https://doi.org/10.1074/jbc.272.40.25380.
• 21.
  Jamaluddin, M.S.; Yang, X.; Wang H.Hyperhomocysteinemia, DNA methylation and vascular disease. Clin. Chem. Lab. Med. 2007, 45, 1660–1666. https://doi.org/10.1515/CCLM.2007.350.
• 22.
  Shen, H.; Wu, N.; Nanayakkara, G.; et al. Co-signaling receptors regulate T-cell plasticity and immune tolerance. Front. Biosci. 2019, 24, 96–132.
• 23.
  Lai, B.; Wang, J.; Fagenson, A.; et al. Twenty Novel Disease Group-Specific and 12 New Shared Macrophage Pathways in Eight Groups of 34 Diseases Including 24 Inflammatory Organ Diseases and 10 Types of Tumors. Front. Immunol. 2019, 10, 2612. https://doi.org/10.3389/fimmu.2019.02612.
• 24.
  Kim, J.E.; Patel, K.; Jackson C.M.The potential for immune checkpoint modulators in cerebrovascular injury and inflammation. Expert. Opin. Ther. Targets 2021, 25, 101–113. https://doi.org/10.1080/14728222.2021.1869213.
• 25.
  Yan, J.; Chen, G.; Gong, J.; et al. Upregulation of OX40-OX40 ligand system on T lymphocytes in patients with acute coronary syndromes. J. Cardiovasc. Pharmacol. 2009, 54, 451–455. https://doi.org/10.1097/FJC.0b013e3181be7578.
• 26.
  Zhang, Q.H.; Yin, R.X.; Chen, W.X.; et al. Association between the TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy. Biosci. Rep. 2018, 38, BSR20171058 https://doi.org/10.1042/BSR20171058.
• 27.
  Drobni, Z.D.; Alvi, R.M.; Taron, J.; et al. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation 2020, 142, 2299–2311. https://doi.org/10.1161/CIRCULATIONAHA.120.049981.
• 28.
  Oren, O.; Yang, E.H.; Molina, J.R.; et al. Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors. Am. J. Cardiol. 2020, 125, 1920–1926. https://doi.org/10.1016/j.amjcard.2020.02.016.
• 29.
  Piras, L.; Zuccanti, M.; Russo, P.; et al. Association between Immune Checkpoint Inhibitors and Atherosclerotic Cardiovascular Disease Risk: Another Brick in the Wall. Int. J. Mol. Sci. 2024, 25, 2502. https://doi.org/10.3390/ijms25052502.
• 30.
  Achim, A.; Liblik, K.; Gevaert S.Immune checkpoint inhibitors—The revolutionary cancer immunotherapy comes with a cardiotoxic price. Trends Cardiovasc. Med. 2024, 34, 71–77. https://doi.org/10.1016/j.tcm.2022.09.004.
• 31.
  Shao, Y.; Saaoud, F.; Xu, K.; et al. Cardiovascular Disease Risk Factors. Immune Checkpoints and Tregs. In Environmental Factors in the Pathogenesis of Cardiovascular Diseases, Agrawal, D., Ed.; Springer: Cham, Switzerland, 2024; Volume 30, pp. 51–93.
• 32.
  Simons, K.H.; de Jong, A.; Jukema, J.W.; et al. T cell co-stimulation and co-inhibition in cardiovascular disease: A double-edged sword. Nat. Rev. Cardiol. 2019, 16, 325–343. https://doi.org/10.1038/s41569-019-0164-7.
• 33.
  Yang, X.F.; Yin, Y.; Wang H.Vascular inflammation and atherogenesis are activated via receptors for pamps and suppressed by regulatory T cells. Drug Discov. Today Ther. Strateg. 2008, 5, 125–142. https://doi.org/10.1016/j.ddstr.2008.11.003.
• 34.
  Pastrana, J.L.; Sha, X.; Virtue, A.; et al. Regulatory T cells and Atherosclerosis. J. Clin. Exp. Cardiol. 2012, 2012, 2. https://doi.org/10.4172/2155-9880.S12-002.
• 35.
  Simons, K.H.; Peters, H.; Arens, R.; et al. P188Co-stimulation dependent CD8 T cell activation protects vein graft disease. Cardiovasc. Res. 2018, 114, S50. https://doi.org/10.1093/cvr/cvy060.145.
• 36.
  Furukawa, Y.; Mandelbrot, D.A.; Libby, P.; et al. Association of B7-1 co-stimulation with the development of graft arterial disease. Studies using mice lacking B7-1, B7-2, or B7-1/B7-2. Am. J. Pathol. 2000, 157, 473–484. https://doi.org/10.1016/S0002-9440(10)64559-2.
• 37.
  Buono, C.; Pang, H.; Uchida, Y.; et al. B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2004, 109, 2009–2015. https://doi.org/10.1161/01.CIR.0000127121.16815.F1.
• 38.
  Matsumoto, T.; Sasaki, N.; Yamashita, T.; et al. Overexpression of Cytotoxic T-Lymphocyte-Associated Antigen-4 Prevents Atherosclerosis in Mice. Arterioscler. Thromb. Vasc. Biol. 2016, 36, 1141–1151. https://doi.org/10.1161/ATVBAHA.115.306848.
• 39.
  Bu, D.X.; Tarrio, M.; Maganto-Garcia, E.; et al. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 1100–1107. https://doi.org/10.1161/ATVBAHA.111.224709.
• 40.
  Gotsman, I.; Grabie, N.; Dacosta, R.; et al. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J. Clin. Invest. 2007, 117, 2974–2982. https://doi.org/10.1172/JCI31344.
• 41.
  Tarrio, M.L.; Grabie, N.; Bu, D.X.; et al. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J. Immunol. 2012, 188, 4876–4884. https://doi.org/10.4049/jimmunol.1200389.
• 42.
  Okazaki, T.; Tanaka, Y.; Nishio, R.; et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 2003, 9, 1477–1483. https://doi.org/10.1038/nm955.
• 43.
  Kallikourdis, M.; Martini, E.; Carullo, P.; et al. T cell costimulation blockade blunts pressure overload-induced heart failure. Nat. Commun. 2017, 8, 14680. https://doi.org/10.1038/ncomms14680.
• 44.
  Ridker, P.M.; Everett, B.M.; Thuren, T.; et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N. Engl. J. Med. 2017, 377, 1119–1131. https://doi.org/10.1056/NEJMoa1707914.
• 45.
  Shao, Y.; Yang, W.Y.; Saaoud, F.; et al. IL-35 promotes CD4+Foxp3+ Tregs and inhibits atherosclerosis via maintaining CCR5-amplified Treg-suppressive mechanisms. JCI Insight 2021, 6, 152511. https://doi.org/10.1172/jci.insight.152511.
• 46.
  Russell, M.E.; Hancock, W.W.; Akalin, E.; et al. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J. Clin. Investig. 1996, 97, 833–838. https://doi.org/10.1172/JCI118483.
• 47.
  Hancock, W.W.; Sayegh, M.H.; Zheng, X.G.; et al. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl. Acad. Sci. USA 1996, 93, 13967–13972. https://doi.org/10.1073/pnas.93.24.13967.
• 48.
  Kim, K.S.; Denton, M.D.; Chandraker, A.; et al. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: Differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am. J. Pathol. 2001, 158, 977–986. https://doi.org/10.1016/S0002-9440(10)64044-8.
• 49.
  Xu, K.; Yang, W.Y.; Nanayakkara, G.K.; et al. GATA3, HDAC6, and BCL6 Regulate FOXP3+ Treg Plasticity and Determine Treg Conversion into Either Novel Antigen-Presenting Cell-Like Treg or Th1-Treg. Front. Immunol. 2018, 9, 45. https://doi.org/10.3389/fimmu.2018.00045.
• 50.
  Yang, W.Y.; Shao, Y.; Lopez-Pastrana, J.; et al. Pathological conditions re-shape physiological Tregs into pathological Tregs. Burn. Trauma. 2015, 3, 1–11. https://doi.org/10.1186/s41038-015-0001-0.
• 51.
  Ni, D.; Tang, T.; Lu, Y.; et al. Canonical Secretomes, Innate Immune Caspase-1-, 4/11-Gasdermin D Non-Canonical Secretomes and Exosomes May Contribute to Maintain Treg-Ness for Treg Immunosuppression, Tissue Repair and Modulate Anti-Tumor Immunity via ROS Pathways. Front. Immunol. 2021, 12, 678201. https://doi.org/10.3389/fimmu.2021.678201.
• 52.
  Zhang, R.; Xu, K.; Shao, Y.; et al. Tissue Treg Secretomes and Transcription Factors Shared With Stem Cells Contribute to a Treg Niche to Maintain Treg-Ness With 80% Innate Immune Pathways, and Functions of Immunosuppression and Tissue Repair. Front. Immunol. 2020, 11, 632239. https://doi.org/10.3389/fimmu.2020.632239.
• 53.
  Drummer, C.; Saaoud, F.; Jhala, N.C.; et al. Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages. Front. Immunol. 2023, 14, 1113883. https://doi.org/10.3389/fimmu.2023.1113883.
• 54.
  Drummer, C.; Saaoud, F.; Shao, Y.; et al. Trained Immunity and Reactivity of Macrophages and Endothelial Cells. Arterioscler. Thromb. Vasc. Biol. 2021, 41, 1032–1046. https://doi.org/10.1161/ATVBAHA.120.315452.
• 55.
  Liu, M.; Wu, N.; Xu, K.; et al. Organelle Crosstalk Regulators Are Regulated in Diseases, Tumors, and Regulatory T Cells: Novel Classification of Organelle Crosstalk Regulators. Front. Cardiovasc. Med. 2021, 8, 713170. https://doi.org/10.3389/fcvm.2021.713170.
• 56.
  Shao, Y.; Saredy, J.; Yang, W.Y.; et al. Vascular Endothelial Cells and Innate Immunity. Arterioscler. Thromb. Vasc. Biol. 2020, 40, e138–e152. https://doi.org/10.1161/ATVBAHA.120.314330.
• 57.
  Mai, J.; Nanayakkara, G.; Lopez-Pastrana, J.; et al. Interleukin-17A Promotes Aortic Endothelial Cell Activation via Transcriptionally and Post-translationally Activating p38 MAPK Pathway. J. Biol. Chem. 2016, 291, 4939–4954. https://doi.org/10.1074/jbc.M115.690081.
• 58.
  Mai, J.; Virtue, A.; Shen, J.; et al. An evolving new paradigm: Endothelial cells--conditional innate immune cells. J. Hematol. Oncol. 2013, 6, 61. https://doi.org/10.1186/1756-8722-6-61.
• 59.
  Lu, Y.; Sun, Y.; Xu, K.; et al. Aorta in Pathologies May Function as an Immune Organ by Upregulating Secretomes for Immune and Vascular Cell Activation, Differentiation and Trans-Differentiation-Early Secretomes may Serve as Drivers for Trained Immunity. Front. Immunol. 2022, 13, 858256. https://doi.org/10.3389/fimmu.2022.858256.
• 60.
  Monroy, M.A.; Fang, J.; Li, S.; et al. Chronic kidney disease alters vascular smooth muscle cell phenotype. Front. Biosci. 2015, 20, 784–795. https://doi.org/10.2741/4337.
• 61.
  Yang, X.F.; Weber, G.F.; Cantor H.A novel Bcl-x isoform connected to the T cell receptor regulates apoptosis in T cells. Immunity 1997, 7, 629–639.
• 62.
  Yang, X.F.; Ye, Q.; Press, B.; et al. Analysis of the complex genomic structure of Bcl-x and its relationship to Bcl-x(gamma) expression after CD28-dependent costimulation. Mol. Immunol. 2002, 39, 45–55. https://doi.org/10.1016/s0161-5890(02)00049-4.
• 63.
  Yang, Y.; Xiong, Z.; Zhang, S.; et al. Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors. Biochem. J. 2005, 392, 135–143. https://doi.org/10.1042/BJ20050698.
• 64.
  Yang, Y.; Yang, F.; Xiong, Z.; et al. An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity. Oncogene 2005, 24, 4778–4788. https://doi.org/10.1038/sj.onc.1208666.
• 65.
  Kuske, M.; Haist, M.; Jung, T.; et al. Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses? Cancers 2022, 14, 1710. https://doi.org/10.3390/cancers14071710.
• 66.
  Yousif, L.I.; Tanja, A.A.; de Boer, R.A.; et al. The role of immune checkpoints in cardiovascular disease. Front. Pharmacol. 2022, 13, 989431. https://doi.org/10.3389/fphar.2022.989431.
• 67.
  Suero-Abreu, G.A.; Zanni, M.V.; Neilan T.G.Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management: JACC: CardioOncology State-of-the-Art Review. JACC Cardio Oncol 2022, 4, 598–615. https://doi.org/10.1016/j.jaccao.2022.11.011.
• 68.
  Dai, J.; Fang, P.; Saredy, J.; et al. Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40(+) monocyte differentiation. J. Hematol. Oncol. 2017, 10, 141. https://doi.org/10.1186/s13045-017-0504-1.
• 69.
  Mortezaee, K.; Majidpoor J.Alternative immune checkpoints in immunoregulatory profile of cancer stem cells. Heliyon 2023, 9, e23171. https://doi.org/10.1016/j.heliyon.2023.e23171.
• 70.
  Soundararajan, R.; Fradette, J.J.; Konen, J.M.; et al. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers 2019, 11, 714. https://doi.org/10.3390/cancers11050714.
• 71.
  Yap, C.; Mieremet, A.; de Vries, C.J.M.; et al. Six Shades of Vascular Smooth Muscle Cells Illuminated by KLF4 (Kruppel-Like Factor 4). Arterioscler. Thromb. Vasc. Biol. 2021, 41, 2693–2707. https://doi.org/10.1161/ATVBAHA.121.316600.
• 72.
  Lu, Y.; Sun, Y.; Saaoud, F.; et al. ER stress mediates Angiotensin II-augmented innate immunity memory and facilitates distinct susceptibilities of thoracic from abdominal aorta to aneurysm development. Front. Immunol. 2023, 14, 1268916. https://doi.org/10.3389/fimmu.2023.1268916.
• 73.
  Kovacic, J.C.; Dimmeler, S.; Harvey, R.P.; et al. Endothelial to Mesenchymal Transition in Cardiovascular Disease: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2019, 73, 190–209. https://doi.org/10.1016/j.jacc.2018.09.089.
• 74.
  Meng, L.; Wu, H.; Wu, J.; et al. Mechanisms of immune checkpoint inhibitors: Insights into the regulation of circular RNAS involved in cancer hallmarks. Cell Death Dis. 2024, 15, 3. https://doi.org/10.1038/s41419-023-06389-5.
• 75.
  Anderson, T.S.; Wooster, A.L.; Piersall, S.L.; et al. Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. Semin. Cancer Biol. 2022, 86, 981–996. https://doi.org/10.1016/j.semcancer.2022.02.009.
• 76.
  Zhang, Y.; Zheng J.Functions of Immune Checkpoint Molecules Beyond Immune Evasion. Adv. Exp. Med. Biol.2020, 1248, 201–226. https://doi.org/10.1007/978-981-15-3266-5_9.
• 77.
  Lim, S.; Phillips, J.B.; Madeira da Silva, L.; et al. Interplay between Immune Checkpoint Proteins and Cellular Metabolism. Cancer Res. 2017, 77, 1245–1249. https://doi.org/10.1158/0008-5472.CAN-16-1647.
• 78.
  Zhang, R.; Saredy, J.; Shao, Y.; et al. End-stage renal disease is different from chronic kidney disease in upregulating ROS-modulated proinflammatory secretome in PBMCs—A novel multiple-hit model for disease progression. Redox Biol. 2020, 34, 101460. https://doi.org/10.1016/j.redox.2020.101460.
• 79.
  Yang, X.F.; Chatellard, C.; Lazure, C.; et al. of hydrophilic amino acid residues in the signal peptide/membrane anchor domain of neprilysin (neutral endopeptidase-24.11) results in its cleavage: Role of the position of insertion. Arch. Biochem. Biophys. 1994, 315, 382–386. https://doi.org/10.1006/abbi.1994.1514.
• 80.
  Yang, X.F.; Crine, P.; Boileau G.The nature of topogenic sequences determines the transport competence of topological mutants of neutral endopeptidase-24.11. Biochem. J. 1995, 312, 99–105. https://doi.org/10.1042/bj3120099.
• 81.
  Liu, S.; Xiong, X.; Thomas, S.V.; et al. Analysis for Carom complex, signaling and function by database mining. Front. Biosci. 2016, 21, 856–872. https://doi.org/10.2741/4424.
• 82.
  He, X.; Xu C.Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020, 30, 660–669. https://doi.org/10.1038/s41422-020-0343-4.
• 83.
  Zhong, C.; Yang, X.; Feng, Y.; et al. Trained Immunity: An Underlying Driver of Inflammatory Atherosclerosis. Front. Immunol. 2020, 11, 284. https://doi.org/10.3389/fimmu.2020.00284.
• 84.
  Lu, Y.; Sun, Y.; Drummer, C.; et al. Increased acetylation of H3K14 in the genomic regions that encode trained immunity enzymes in lysophosphatidylcholine-activated human aortic endothelial cells—Novel qualification markers for chronic disease risk factors and conditional DAMPs. Redox Biol. 2019, 24, 101221. https://doi.org/10.1016/j.redox.2019.101221.
• 85.
  Li, X.; Fang, P.; Sun, Y.; et al. Anti-inflammatory cytokines IL-35 and IL-10 block atherogenic lysophosphatidylcholine-induced, mitochondrial ROS-mediated innate immune activation, but spare innate immune memory signature in endothelial cells. Redox Biol. 2020, 28, 101373. https://doi.org/10.1016/j.redox.2019.101373.
• 86.
  Saaoud, F.; Liu, L.; Xu, K.; et al. Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways. JCI Insight 2023, 8, 158183. https://doi.org/10.1172/jci.insight.158183.
• 87.
  Fagenson, A.M.; Xu, K.; Saaoud, F.; et al. Liver Ischemia Reperfusion Injury, Enhanced by Trained Immunity, Is Attenuated in Caspase 1/Caspase 11 Double Gene Knockout Mice. Pathogens 2020, 9, 879. https://doi.org/10.3390/pathogens9110879.
• 88.
  Xu, Y.; He, L.; Fu, Q.; et al. Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints. Front. Oncol. 2021, 11, 759015. https://doi.org/10.3389/fonc.2021.759015.
• 89.
  Man, K.; Miasari, M.; Shi, W.; et al. The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells. Nat. Immunol. 2013, 14, 1155–1165. https://doi.org/10.1038/ni.2710.
• 90.
  Shi, L.Z.; Wang, R.; Huang, G.; et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 2011, 208, 1367–1376. https://doi.org/10.1084/jem.20110278.
• 91.
  Seijkens, T.T.P.; van Tiel, C.M.; Kusters, P.J.H.; et al. Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis. J. Am. Coll. Cardiol. 2018, 71, 527–542. https://doi.org/10.1016/j.jacc.2017.11.055.
• 92.
  Chatzigeorgiou, A.; Seijkens, T.; Zarzycka, B.; et al. Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance. Proc. Natl. Acad. Sci. USA 2014, 111, 2686–2691. https://doi.org/10.1073/pnas.1400419111.
• 93.
  Ewing, M.M.; Karper, J.C.; Abdul, S.; et al. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int. J. Cardiol. 2013, 168, 1965–1974. https://doi.org/10.1016/j.ijcard.2012.12.085.
• 94.
  Ma, K.; Lv, S.; Liu, B.; et al. CTLA4-IgG ameliorates homocysteine-accelerated atherosclerosis by inhibiting T-cell overactivation in apoE(-/-) mice. Cardiovasc. Res. 2013, 97, 349–359. https://doi.org/10.1093/cvr/cvs330.
• 95.
  Wing, K.; Onishi, Y.; Prieto-Martin, P.; et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008, 322, 271–275. https://doi.org/10.1126/science.1160062.
• 96.
  Walker, L.S. Treg and CTLA-4: Two intertwining pathways to immune tolerance. J. Autoimmun. 2013, 45, 49–57. https://doi.org/10.1016/j.jaut.2013.06.006.
• 97.
  Shao, Y.; Saredy, J.; Xu, K.; et al. Endothelial Immunity Trained by Coronavirus Infections, DAMP Stimulations and Regulated by Anti-Oxidant NRF2 May Contribute to Inflammations, Myelopoiesis, COVID-19 Cytokine Storms and Thromboembolism. Front. Immunol. 2021, 12, 653110. https://doi.org/10.3389/fimmu.2021.653110.
• 98.
  Li, X.; Wang, L.; Fang, P.; et al. Lysophospholipids induce innate immune transdifferentiation of endothelial cells, resulting in prolonged endothelial activation. J. Biol. Chem. 2018, 293, 11033–11045. https://doi.org/10.1074/jbc.RA118.002752.
• 99.
  Sun, Y.; Lu, Y.; Liu, L.; et al. Caspase-4/11 promotes hyperlipidemia and chronic kidney disease-accelerated vascular inflammation by enhancing trained immunity. JCI Insight 2024, 9, 177229. https://doi.org/10.1172/jci.insight.177229.
• 100.
  He, S.; Li, M.; Ma, X.; et al. CD4+CD25+Foxp3+ regulatory T cells protect the proinflammatory activation of human umbilical vein endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 2621–2630. https://doi.org/10.1161/ATVBAHA.110.210492.
• 101.
  Xu, K.; Shao, Y.; Saaoud, F.; et al. Novel Knowledge-Based Transcriptomic Profiling of Lipid Lysophosphatidylinositol-Induced Endothelial Cell Activation. Front. Cardiovasc. Med. 2021, 8, 773473. https://doi.org/10.3389/fcvm.2021.773473.
• 102.
  Buchbinder, E.I.; Desai A.CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am. J. Clin. Oncol. 2016, 39, 98–106. https://doi.org/10.1097/COC.0000000000000239.
• 103.
  Sharpe, A.H.; Freeman G.J. The B7-CD28 superfamily. Nat. Rev. Immunol. 2002, 2, 116–126. https://doi.org/10.1038/nri727.
• 104.
  Keir, M.E.; Butte, M.J.; Freeman, G.J.; et al. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26, 677–704. https://doi.org/10.1146/annurev.immunol.26.021607.090331.
• 105.
  Cochain, C.; Chaudhari, S.M.; Koch, M.; et al. Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice. PLoS ONE 2014, 9, e93280. https://doi.org/10.1371/journal.pone.0093280.
• 106.
  Yang, Q.; Saaoud, F.; Lu, Y.; et al. Innate immunity of vascular smooth muscle cells contributes to two-wave inflammation in atherosclerosis, twin-peak inflammation in aortic aneurysms and trans-differentiation potential into 25 cell types. Front. Immunol. 2023, 14, 1348238. https://doi.org/10.3389/fimmu.2023.1348238.
• 107.
  Schiller, N.K.; Kubo, N.; Boisvert, W.A.; et al. Effect of gamma-irradiation and bone marrow transplantation on atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 1674–1680. https://doi.org/10.1161/hq1001.096724.
• 108.
  Lacy, M.; Burger, C.; Shami, A.; et al. Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease. Nat. Commun. 2021, 12, 3754. https://doi.org/10.1038/s41467-021-23909-z.
• 109.
  Kumagai, S.; Togashi, Y.; Kamada, T.; et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat. Immunol. 2020, 21, 1346–1358. https://doi.org/10.1038/s41590-020-0769-3.
• 110.
  Kamada, T.; Togashi, Y.; Tay, C.; et al. PD-1(+‍) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc. Natl. Acad. Sci. USA 2019, 116, 9999–10008. https://doi.org/10.1073/pnas.1822001116.
• 111.
  Ait-Oufella, H.; Salomon, B.L.; Potteaux, S.; et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 2006, 12, 178–180.
• 112.
  Gotsman, I.; Grabie, N.; Gupta, R.; et al. regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 2006, 114, 2047–2055. https://doi.org/10.1161/CIRCULATIONAHA.106.633263.
• 113.
  Francisco, L.M.; Salinas, V.H.; Brown, K.E.; et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 2009, 206, 3015–3029. https://doi.org/10.1084/jem.20090847.
• 114.
  Yang, Q.; Nanayakkara, G.K.; Drummer, C.; et al. Low-Intensity Ultrasound-Induced Anti-inflammatory Effects Are Mediated by Several New Mechanisms Including Gene Induction, Immunosuppressor Cell Promotion, and Enhancement of Exosome Biogenesis and Docking. Front. Physiol. 2017, 8, 818. https://doi.org/10.3389/fphys.2017.00818.
• 115.
  Yodoi, K.; Yamashita, T.; Sasaki, N.; et al. Foxp3+ regulatory T cells play a protective role in angiotensin II-induced aortic aneurysm formation in mice. Hypertension 2015, 65, 889–895. https://doi.org/10.1161/HYPERTENSIONAHA.114.04934.
• 116.
  Hayashi, T.; Sasaki, N.; Yamashita, T.; et al. Ultraviolet B Exposure Inhibits Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Mice by Expanding CD4(+)Foxp3(+) Regulatory T Cells. J. Am. Heart Assoc. 2017, 6, e007024. https://doi.org/10.1161/JAHA.117.007024.
• 117.
  Sugiura, D.; Maruhashi, T.; Okazaki, I.M.; et al. Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science 2019, 364, 558–566. https://doi.org/10.1126/science.aav7062.
• 118.
  Zhao, Y.; Lee, C.K.; Lin, C.H.; et al. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity 2019, 51, 1059–1073. https://doi.org/10.1016/j.immuni.2019.11.003.
• 119.
  Tekguc, M.; Wing, J.B.; Osaki, M.; et al. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc. Natl. Acad. Sci. USA 2021, 118, e2023739118. https://doi.org/10.1073/pnas.2023739118.
• 120.
  Amin, H.Z.; Sasaki, N.; Yamashita, T.; et al. CTLA-4 Protects against Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Mice. Sci. Rep. 2019, 9, 8065. https://doi.org/10.1038/s41598-019-44523-6.
• 121.
  Sun, P.; Zhang, L.; Gu, Y.; et al. Immune checkpoint programmed death-1 mediates abdominal aortic aneurysm and pseudoaneurysm progression. Biomed. Pharmacother. 2021, 142, 111955. https://doi.org/10.1016/j.biopha.2021.111955.
• 122.
  Chu, X.; Tian, W.; Wang, Z.; et al. Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials. Mol. Cancer 2023, 22, 93. https://doi.org/10.1186/s12943-023-01800-3.
• 123.
  Levin, S.D.; Taft, D.W.; Brandt, C.S.; et al. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur. J. Immunol. 2011, 41, 902–915. https://doi.org/10.1002/eji.201041136.
• 124.
  Harjunpaa, H.; Guillerey C.TIGIT as an emerging immune checkpoint. Clin. Exp. Immunol.2020, 200, 108–119. https://doi.org/10.1111/cei.13407.
• 125.
  Kurtulus, S.; Sakuishi, K.; Ngiow, S.F.; et al. TIGIT predominantly regulates the immune response via regulatory T cells. J. Clin. Investig. 2015, 125, 4053–4062. https://doi.org/10.1172/JCI81187.
• 126.
  Saleh, R.; Elkord E.Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Lett. 2019, 457, 168–179. https://doi.org/10.1016/j.canlet.2019.05.003.
• 127.
  Lucca, L.E.; Axisa, P.P.; Singer, E.R.; et al. TIGIT signaling restores suppressor function of Th1 Tregs. JCI Insight 2019, 4, 124427. https://doi.org/10.1172/jci.insight.124427.
• 128.
  Joller, N.; Lozano, E.; Burkett, P.R.; et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 2014, 40, 569–581. https://doi.org/10.1016/j.immuni.2014.02.012.
• 129.
  Foks, A.C.; Ran, I.A.; Frodermann, V.; et al. Agonistic anti-TIGIT treatment inhibits T cell responses in LDLr deficient mice without affecting atherosclerotic lesion development. PLoS ONE 2013, 8, e83134. https://doi.org/10.1371/journal.pone.0083134.
• 130.
  Butcher, M.J.; Filipowicz, A.R.; Waseem, T.C.; et al. Atherosclerosis-Driven Treg Plasticity Results in Formation of a Dysfunctional Subset of Plastic IFNgamma+ Th1/Tregs. Circ. Res. 2016, 119, 1190–1203. https://doi.org/10.1161/CIRCRESAHA.116.309764.
• 131.
  Fuhrman, C.A.; Yeh, W.I.; Seay, H.R.; et al. Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226. J. Immunol. 2015, 195, 145–155. https://doi.org/10.4049/jimmunol.1402381.
• 132.
  Thornton, A.M.; Lu, J.; Korty, P.E.; et al. Helios(+) and Helios(-) Treg subpopulations are phenotypically and functionally distinct and express dissimilar TCR repertoires. Eur. J. Immunol. 2019, 49, 398–412. https://doi.org/10.1002/eji.201847935.
• 133.
  Hasan, M.M.; Nair, S.S.; O’Leary, J.G.; et al. Implication of TIGIT(+) human memory B cells in immune regulation. Nat. Commun. 2021, 12, 1534. https://doi.org/10.1038/s41467-021-21413-y.
• 134.
  Ding, Q.Q.; Chauvin, J.M.; Zarour H.M.Targeting novel inhibitory receptors in cancer immunotherapy. Semin. Immunol. 2020, 49, 101436. https://doi.org/10.1016/j.smim.2020.101436.
• 135.
  Rouwet, E.; Lutgens, E. 2016 Jeffrey M. Hoeg Award Lecture. Arterioscler. Thromb. Vasc. Biol. 2018, 38, 1678–1688. https://doi.org/10.1161/ATVBAHA.118.307742.
• 136.
  Jin, H.S.; Park Y.Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy. BMB Rep. 2021, 54, 2–11.
• 137.
  Zhao, T.V.; Hu, Z.; Ohtsuki, S.; et al. Hyperactivity of the CD155 immune checkpoint suppresses anti-viral immunity in patients with coronary artery disease. Nat. Cardiovasc. Res. 2022, 1, 634–648. https://doi.org/10.1038/s44161-022-00096-8.
• 138.
  Watanabe, R.; Hilhorst, M.; Zhang, H.; et al. Glucose metabolism controls disease-specific signatures of macrophage effector functions. JCI Insight 2018, 3, 123047. https://doi.org/10.1172/jci.insight.123047.
• 139.
  Monney, L.; Sabatos, C.A.; Gaglia, J.L.; et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415, 536–541. https://doi.org/10.1038/415536a.
• 140.
  Nakayama, M.; Akiba, H.; Takeda, Ket al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 2009, 113, 3821–3830. https://doi.org/10.1182/blood-2008-10-185884.
• 141.
  Krautter, F.; Hussain, M.T.; Zhi, Z.; et al. Galectin-9: A novel promoter of atherosclerosis progression. Atherosclerosis 2022, 363, 57–68. https://doi.org/10.1016/j.atherosclerosis.2022.11.014.
• 142.
  Foks, A.C.; Ran, I.A.; Wasserman, L.; et al. T-cell immunoglobulin and mucin domain 3 acts as a negative regulator of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 2558–2565. https://doi.org/10.1161/ATVBAHA.113.301879.
• 143.
  Yang, H.; Wang, H.; Andersson U.Targeting Inflammation Driven by HMGB1. Front. Immunol. 2020, 11, 484. https://doi.org/10.3389/fimmu.2020.00484.
• 144.
  Chiba, S.; Baghdadi, M.; Akiba, H.; et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 2012, 13, 832–842. https://doi.org/10.1038/ni.2376.
• 145.
  Andersson, U.; Yang, H.; Harris H. High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. Semin. Immunol. 2018, 38, 40–48. https://doi.org/10.1016/j.smim.2018.02.011.
• 146.
  Xu, K.; Saaoud, F.; Shao, Y.; et al. A new paradigm in intracellular immunology: Mitochondria emerging as leading immune organelles. Redox Biol. 2024, 76, 103331. https://doi.org/10.1016/j.redox.2024.103331.
• 147.
  Sun, Y.; Lu, Y.; Saredy, J.; et al. ROS systems are a new integrated network for sensing homeostasis and alarming stresses in organelle metabolic processes. Redox Biol. 2020, 37, 101696.
• 148.
  Li, X.; Fang, P.; Li, Y.; et al. Mitochondrial Reactive Oxygen Species Mediate Lysophosphatidylcholine-Induced Endothelial Cell Activation. Arterioscler. Thromb. Vasc. Biol. 2016, 36, 1090–1100. https://doi.org/10.1161/ATVBAHA.115.306964.
• 149.
  Li, X.; Fang, P.; Yang, W.Y.; et al. Mitochondrial ROS, uncoupled from ATP synthesis, determine endothelial activation for both physiological recruitment of patrolling cells and pathological recruitment of inflammatory cells. Can. J. Physiol. Pharmacol. 2017, 95, 247–252. https://doi.org/10.1139/cjpp-2016-0515.
• 150.
  Li, X.; Shao, Y.; Sha, X.; et al. IL-35 (Interleukin-35) Suppresses Endothelial Cell Activation by Inhibiting Mitochondrial Reactive Oxygen Species-Mediated Site-Specific Acetylation of H3K14 (Histone 3 Lysine 14). Arterioscler. Thromb. Vasc. Biol. 2018, 38, 599–609. https://doi.org/10.1161/ATVBAHA.117.310626.
• 151.
  Nanayakkara, G.K.; Wang, H.; Yang X.Proton leak regulates mitochondrial reactive oxygen species generation in endothelial cell activation and inflammation—A novel concept. Arch. Biochem. Biophys. 2019, 662, 68–74. https://doi.org/10.1016/j.abb.2018.12.002.
• 152.
  Boytard, L.; Hadi, T.; Silvestro, M.; et al. Lung-derived HMGB1 is detrimental for vascular remodeling of metabolically imbalanced arterial macrophages. Nat. Commun. 2020, 11, 4311. https://doi.org/10.1038/s41467-020-18088-2.
• 153.
  Sharma, A.K.; Salmon, M.D.; Lu, G.; et al. Mesenchymal Stem Cells Attenuate NADPH Oxidase-Dependent High Mobility Group Box 1 Production and Inhibit Abdominal Aortic Aneurysms. Arterioscler. Thromb. Vasc. Biol. 2016, 36, 908–918. https://doi.org/10.1161/ATVBAHA.116.307373.
• 154.
  Chou, E.L.; Chaffin, M.; Simonson, B.; et al. Aortic Cellular Diversity and Quantitative Genome-Wide Association Study Trait Prioritization Through Single-Nuclear RNA Sequencing of the Aneurysmal Human Aorta. Arterioscler. Thromb. Vasc. Biol. 2022, 42, 1355–1374. https://doi.org/10.1161/ATVBAHA.122.317953.
• 155.
  Qiu, M.K.; Wang, S.C.; Dai, Y.X.; et al. PD-1 and Tim-3 Pathways Regulate CD8+ T Cells Function in Atherosclerosis. PLoS ONE 2015, 10, e0128523. https://doi.org/10.1371/journal.pone.0128523.
• 156.
  Tieu, R.; Amancha, P.K.; Villinger, F.; et al. TIM-3, a Possible Target for Immunotherapy in Cancer and Chronic Viral Infections. Austin Virol. Retro Virol. 2014, 1, 6.
• 157.
  Jubel, J.M.; Barbati, Z.R.; Burger, C.; et al. The Role of PD-1 in Acute and Chronic Infection. Front. Immunol. 2020, 11, 487. https://doi.org/10.3389/fimmu.2020.00487.
• 158.
  Goldberg, M.V.; Drake C.G.LAG-3 in Cancer Immunotherapy. Curr. Top. Microbiol. Immunol. 2011, 344, 269–278. https://doi.org/10.1007/82_2010_114.
• 159.
  Mulholland, M.; Kritikou, E.; Katra, P.; et al. LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice. JACC Cardio Oncol. 2022, 4, 635–645. https://doi.org/10.1016/j.jaccao.2022.09.005.
• 160.
  Gao, Z.; Liu, Z.; Wang, R.; et al. Galectin-3 Is a Potential Mediator for Atherosclerosis. J. Immunol. Res. 2020, 2020, 5284728. https://doi.org/10.1155/2020/5284728.
• 161.
  Chen, S.S.; Sun, L.W.; Brickner, H.; et al. Downregulating galectin-3 inhibits proinflammatory cytokine production by human monocyte-derived dendritic cells via RNA interference. Cell Immunol. 2015, 294, 44–53. https://doi.org/10.1016/j.cellimm.2015.01.017.
• 162.
  Arar, C.; Gaudin, J.C.; Capron, L.; et al. Galectin-3 gene (LGALS3) expression in experimental atherosclerosis and cultured smooth muscle cells. FEBS Lett. 1998, 430, 307–311. https://doi.org/10.1016/s0014-5793(98)00683-8.
• 163.
  Nachtigal, M.; Al-Assaad, Z.; Mayer, E.P.; et al. Galectin-3 expression in human atherosclerotic lesions. Am. J. Pathol. 1998, 152, 1199–1208.
• 164.
  MacKinnon, A.C.; Liu, X.; Hadoke, P.W.; et al. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology 2013, 23, 654–663. https://doi.org/10.1093/glycob/cwt006.
• 165.
  Sharma, U.C.; Pokharel, S.; van Brakel, T.J.; et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110, 3121–3128. https://doi.org/10.1161/01.CIR.0000147181.65298.4D.
• 166.
  Ho, J.E.; Liu, C.; Lyass, A.; et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J. Am. Coll. Cardiol. 2012, 60, 1249–1256. https://doi.org/10.1016/j.jacc.2012.04.053.
• 167.
  Gullestad, L.; Ueland, T.; Kjekshus, J.; et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur. Heart J. 2012, 33, 2290–2296. https://doi.org/10.1093/eurheartj/ehs077.
• 168.
  Tsai, T.H.; Sung, P.H.; Chang, L.T.; et al. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J. Atheroscler. Thromb. 2012, 19, 1073–1082. https://doi.org/10.5551/jat.12856.
• 169.
  de Boer, R.A.; van Veldhuisen, D.J.; Gansevoort, R.T.; et al. The fibrosis marker galectin-3 and outcome in the general population. J. Intern. Med. 2012, 272, 55–64. https://doi.org/10.1111/j.1365-2796.2011.02476.x.
• 170.
  Fernandez-Garcia, C.E.; Tarin, C.; Roldan-Montero, R.; et al. Increased galectin-3 levels are associated with abdominal aortic aneurysm progression and inhibition of galectin-3 decreases elastase-induced AAA development. Clin Sci (Lond) 2017, 131, 2707–2719. https://doi.org/10.1042/CS20171142.
• 171.
  Menini, S.; Iacobini, C.; Ricci, C.; et al. The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. Cardiovasc. Res. 2013, 100, 472–480. https://doi.org/10.1093/cvr/cvt206.
• 172.
  Fehervari, Z. Don’t eat me, activate me. Nat. Immunol. 2015, 16, 1113. https://doi.org/10.1038/ni.3303.
• 173.
  Liu, X.; Pu, Y.; Cron, K.; et al. CD47 blockade triggers T cell–mediated destruction of immunogenic tumors. Nat. Med. 2015, 21, 1209–1215. https://doi.org/10.1038/nm.3931.
• 174.
  Brooke, G.; Holbrook, J.D.; Brown, M.H.; et al. Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family. J. Immunol. 2004, 173, 2562–2570. https://doi.org/10.4049/jimmunol.173.4.2562.
• 175.
  Logtenberg, M.E.W.; Scheeren, F.A.; Schumacher T.N.The CD47-SIRPalpha Immune Checkpoint. Immunity 2020, 52, 742–752. https://doi.org/10.1016/j.immuni.2020.04.011.
• 176.
  Schrijvers, D.M.; De Meyer, G.R.; Kockx, M.M.; et al. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1256–1261. https://doi.org/10.1161/01.ATV.0000166517.18801.a7.
• 177.
  Yurdagul A., Jr.; Doran, A.C.; Cai, B.; et al. Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis. Front. Cardiovasc. Med. 2017, 4, 86. https://doi.org/10.3389/fcvm.2017.00086.
• 178.
  Kojima, Y.; Volkmer, J.P.; McKenna, K.; et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 2016, 536, 86–90. https://doi.org/10.1038/nature18935.
• 179.
  Jarr, K.U.; Nakamoto, R.; Doan, B.H.; et al. Effect of CD47 Blockade on Vascular Inflammation. N. Engl. J. Med. 2021, 384, 382–383. https://doi.org/10.1056/NEJMc2029834.
• 180.
  Singla, B.; Lin, H.P.; Ahn, W.; et al. Loss of myeloid cell-specific SIRPalpha, but not CD47, attenuates inflammation and suppresses atherosclerosis. Cardiovasc. Res. 2022, 118, 3097–3111. https://doi.org/10.1093/cvr/cvab369.
• 181.
  Dong, Z.M.; Brown, A.A.; Wagner D.D.Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation 2000, 101, 2290–2295. https://doi.org/10.1161/01.cir.101.19.2290.
• 182.
  Volcik, K.A.; Catellier, D.; Folsom, A.R.; et al. SELP and SELPLG genetic variation is associated with cell surface measures of SELP and SELPLG: The Atherosclerosis Risk in Communities Carotid MRI Study. Clin. Chem. 2009, 55, 1076–1082. https://doi.org/10.1373/clinchem.2008.119487.
• 183.
  Wang, L.; Rubinstein, R.; Lines, J.L.; et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 2011, 208, 577–592. https://doi.org/10.1084/jem.20100619.
• 184.
  Johnston, R.J.; Su, L.J.; Pinckney, J.; et al. VISTA is an acidic pH-selective ligand for PSGL-1. Nature 2019, 574, 565–570. https://doi.org/10.1038/s41586-019-1674-5.
• 185.
  Naghavi, M.; John, R.; Naguib, S.; et al. pH Heterogeneity of human and rabbit atherosclerotic plaques: A new insight into detection of vulnerable plaque. Atherosclerosis 2002, 164, 27–35. https://doi.org/10.1016/s0021-9150(02)00018-7.
• 186.
  Liu, C.L.; Zhang, X.; Liu, J.; et al. Na(+)-H(+) exchanger 1 determines atherosclerotic lesion acidification and promotes atherogenesis. Nat. Commun. 2019, 10, 3978. https://doi.org/10.1038/s41467-019-11983-3.
• 187.
  Li, N.; Xu, W.; Yuan, Y.; et al. Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis. Sci. Rep. 2017, 7, 1485. https://doi.org/10.1038/s41598-017-01411-1.
• 188.
  Gray, C.C.; Biron-Girard, B.; Wakeley, M.E.; et al. Negative Immune Checkpoint Protein, VISTA, Regulates the CD4(+) T(reg) Population During Sepsis Progression to Promote Acute Sepsis Recovery and Survival. Front. Immunol. 2022, 13, 861670. https://doi.org/10.3389/fimmu.2022.861670.
• 189.
  Daub, S.; Lutgens, E.; Munzel, T.; et al. CD40/CD40L and Related Signaling Pathways in Cardiovascular Health and Disease-The Pros and Cons for Cardioprotection. Int. J. Mol. Sci. 2020, 21, 8533. https://doi.org/10.3390/ijms21228533.
• 190.
  Yang, J.; Fang, P.; Yu, D.; et al. Chronic Kidney Disease Induces Inflammatory CD40+ Monocyte Differentiation via Homocysteine Elevation and DNA Hypomethylation. Circ. Res. 2016, 119, 1226–1241. https://doi.org/10.1161/CIRCRESAHA.116.308750.
• 191.
  Tang, T.; Cheng, X.; Truong, B.; et al. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacol. Ther. 2021, 219, 107709. https://doi.org/10.1016/j.pharmthera.2020.107709.
• 192.
  Cipollone, F.; Mezzetti, A.; Porreca, E.; et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: Effects of statin therapy. Circulation 2002, 106, 399–402. https://doi.org/10.1161/01.cir.0000025419.95769.f0.
• 193.
  Heeschen, C.; Dimmeler, S.; Hamm, C.W.; et al. Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. 2003, 348, 1104–1111. https://doi.org/10.1056/NEJMoa022600.
• 194.
  Mach, F.; Schonbeck, U.; Sukhova, G.K.; et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998, 394, 200–203. https://doi.org/10.1038/28204.
• 195.
  Schonbeck, U.; Sukhova, G.K.; Shimizu, K.; et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 2000, 97, 7458–7463. https://doi.org/10.1073/pnas.97.13.7458.
• 196.
  Lutgens, E.; Gorelik, L.; Daemen, M.J.; et al. Requirement for CD154 in the progression of atherosclerosis. Nat. Med. 1999, 5, 1313–1316. https://doi.org/10.1038/15271.
• 197.
  Lutgens, E.; Lievens, D.; Beckers, L.; et al. CD40 and its ligand in atherosclerosis. Trends Cardiovasc. Med. 2007, 17, 118–123. https://doi.org/10.1016/j.tcm.2007.02.004.
• 198.
  Bavendiek, U.; Zirlik, A.; LaClair, S.; et al. Atherogenesis in mice does not require CD40 ligand from bone marrow-derived cells. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1244–1249. https://doi.org/10.1161/01.ATV.0000161420.55482.ef.
• 199.
  Smook, M.L.; Heeringa, P.; Damoiseaux, J.G.; et al. eukocyte CD40L deficiency affects the CD25(+) CD4 T cell population but does not affect atherosclerosis. Atherosclerosis 2005, 183, 275–282. https://doi.org/10.1016/j.atherosclerosis.2005.03.051.
• 200.
  Lievens, D.; Zernecke, A.; Seijkens, T.; et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010, 116, 4317–4327. https://doi.org/10.1182/blood-2010-01-261206.
• 201.
  Simons, K.H.; Aref, Z.; Peters, H.A.B.; et al. The role of CD27-CD70-mediated T cell co-stimulation in vasculogenesis, arteriogenesis and angiogenesis. Int. J. Cardiol. 2018, 260, 184–190. https://doi.org/10.1016/j.ijcard.2018.02.015.
• 202.
  Winkels, H.; Meiler, S.; Smeets, E.; et al. CD70 limits atherosclerosis and promotes macrophage function. Thromb. Haemost. 2017, 117, 164–175. https://doi.org/10.1160/TH16-04-0318.
• 203.
  Coquet, J.M.; Ribot, J.C.; Babala, N.; et al. Epithelial and dendritic cells in the thymic medulla promote CD4+Foxp3+ regulatory T cell development via the CD27-CD70 pathway. J. Exp. Med. 2013, 210, 715–728. https://doi.org/10.1084/jem.20112061.
• 204.
  Winkels, H.; Meiler, S.; Lievens, D.; et al. CD27 co-stimulation increases the abundance of regulatory T cells and reduces atherosclerosis in hyperlipidaemic mice. Eur. Heart J. 2017, 38, 3590–3599. https://doi.org/10.1093/eurheartj/ehx517.
• 205.
  Herrero-Cervera, A.; Espinos-Estevez, C.; Martin-Vano, S.; et al. Dissecting Abdominal Aortic Aneurysm Is Aggravated by Genetic Inactivation of LIGHT (TNFSF14). Biomedicines 2021, 9, 1518. https://doi.org/10.3390/biomedicines9111518.
• 206.
  Lee, W.H.; Kim, S.H.; Lee, Y.; et al. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 2004–2010. https://doi.org/10.1161/hq1201.098945.
• 207.
  Murphy, T.L.; Murphy K.M.Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM. Annu. Rev. Immunol. 2010, 28, 389–411. https://doi.org/10.1146/annurev-immunol-030409-101202.
• 208.
  Steinberg, M.W.; Cheung, T.C.; Ware C.F.The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunol. Rev. 2011, 244, 169–187. https://doi.org/10.1111/j.1600-065X.2011.01064.x.
• 209.
  Lin, J.D.; Nishi, H.; Poles, J.; et al. Single-cell analysis of fate-mapped macrophages reveals heterogeneity, including stem-like properties, during atherosclerosis progression and regression. JCI Insight 2019, 4, 124574. https://doi.org/10.1172/jci.insight.124574.
• 210.
  Cai, G.; Anumanthan, A.; Brown, J.A.; et al. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat. Immunol. 2008, 9, 176–185. https://doi.org/10.1038/ni1554.
• 211.
  Zuo, J.; Shan, Z.; Zhou, L.; et al. Increased CD160 expression on circulating natural killer cells in atherogenesis. J. Transl. Med. 2015, 13, 188. https://doi.org/10.1186/s12967-015-0564-3.
• 212.
  Dolade, N.; Rayego-Mateos, S.; Garcia-Carrasco, A.; et al. B- and T-lymphocyte attenuator could be a new player in accelerated atherosclerosis associated with chronic kidney disease. Clin. Sci. 2023, 137, 1409–1429. https://doi.org/10.1042/CS20230399.
• 213.
  Nocentini, G.; Riccardi, C. GITR: A modulator of immune response and inflammation. Adv. Exp. Med. Biol. 2009, 647, 156–173. https://doi.org/10.1007/978-0-387-89520-8_11.
• 214.
  Meiler, S.; Smeets, E.; Winkels, H.; et al. Constitutive GITR Activation Reduces Atherosclerosis by Promoting Regulatory CD4+ T-Cell Responses-Brief Report. Arterioscler. Thromb. Vasc. Biol. 2016, 36, 1748–1752. https://doi.org/10.1161/ATVBAHA.116.307354.
• 215.
  Shami, A.; Atzler, D.; Bosmans, L.A.; et al. Glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR) drives atherosclerosis in mice and is associated with an unstable plaque phenotype and cerebrovascular events in humans. Eur. Heart J. 2020, 41, 2938–2948. https://doi.org/10.1093/eurheartj/ehaa484.
• 216.
  Arestides, R.S.; He, H.; Westlake, R.M.; et al. Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation. Eur. J. Immunol. 2002, 32, 2874–2880. https://doi.org/10.1002/1521-4141(2002010)32:10<2874::AID-IMMU2874>3.0.CO;2-4.
• 217.
  Wang, X.; Ria, M.; Kelmenson, P.M.; et al. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat. Genet. 2005, 37, 365–372. https://doi.org/10.1038/ng1524.
• 218.
  van Wanrooij, E.J.; van Puijvelde, G.H.; de Vos, P.; et al. Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 204–210. https://doi.org/10.1161/01.ATV.0000251007.07648.81.
• 219.
  Binder, C.J.; Hartvigsen, K.; Chang, M.K.; et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 2004, 114, 427–437. https://doi.org/10.1172/JCI20479.
• 220.
  Miller, A.M.; Xu, D.; Asquith, D.L.; et al. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 2008, 205, 339–346.
• 221.
  Nakae, S.; Suto, H.; Iikura, M.; et al. Mast cells enhance T cell activation: Importance of mast cell costimulatory molecules and secreted TNF. J. Immunol. 2006, 176, 2238–2248. https://doi.org/10.4049/jimmunol.176.4.2238.
• 222.
  Wang, H.; Jiang, X.; Yang, F.; et al. Hyperhomocysteinemia accelerates atherosclerosis in cystathionine beta-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. Blood 2003, 101, 3901–3907. https://doi.org/10.1182/blood-2002-08-2606.
• 223.
  Safarzadeh, A.; Alizadeh, M.; Beyranvand, F.; et al. Varied functions of immune checkpoints during cancer metastasis. Cancer Immunol. Immunother. 2021, 70, 569–588. https://doi.org/10.1007/s00262-020-02717-2.
• 224.
  Zhou, K.; Li, S.; Zhao, Y.; et al. Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer. Front. Immunol. 2023, 14, 1127071. https://doi.org/10.3389/fimmu.2023.1127071.
• 225.
  Soto-Pantoja, D.R.; Kaur, S.; Roberts D.D.CD47 signaling pathways controlling cellular differentiation and responses to stress. Crit. Rev. Biochem. Mol. Biol.2015, 50, 212–230. https://doi.org/10.3109/10409238.2015.1014024.